US20130011446A1 - Ceramic composition for filling bone defects - Google Patents
Ceramic composition for filling bone defects Download PDFInfo
- Publication number
- US20130011446A1 US20130011446A1 US13/614,369 US201213614369A US2013011446A1 US 20130011446 A1 US20130011446 A1 US 20130011446A1 US 201213614369 A US201213614369 A US 201213614369A US 2013011446 A1 US2013011446 A1 US 2013011446A1
- Authority
- US
- United States
- Prior art keywords
- composition
- glass
- ranging
- glycerol
- carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/46—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
- A61L27/3843—Connective tissue
- A61L27/3847—Bones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/446—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with other specific inorganic fillers other than those covered by A61L27/443 or A61L27/46
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/406—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/408—Virucides, spermicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
- A61L2300/622—Microcapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
- A61L2300/802—Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Definitions
- the present invention is generally directed toward a surgical bioactive glass bone implant product and more specifically is a moldable and shapeable putty composition sterilized by gamma radiation for filling bone defects having a bioactive glass material with a size ranging from 32 to 710 ⁇ m with a weight ranging from 68% to 76% by weight of the composition mixed in a fluid carrier of glycerol and polyethylene glycol.
- Surgical implants should be designed to be biocompatible in order to successfully perform their intended function.
- Biocompatibility may be defined as the characteristic of an implant acting in such a way as to allow its therapeutic function to be manifested without secondary adverse affects such as toxicity, foreign body reaction or cellular disruption.
- Formable compositions are used to correct surgical defects that may be caused by trauma, pathological disease, surgical intervention or other situations where defects need to be managed in osseous surgery. It is important to have the defect filler in the form of a stable, viscous formable composition to facilitate the placement of the composition into the surgical site which is usually uneven in shape and depth. The surgeon will take the composition on a spatula or other instrument and trowel it into the site or take it in his/her fingers to shape the bone defect material into the proper configuration to fit the site being corrected. It is also important that the defect filler be biocompatible.
- Osteogenic bone grafting materials may generally be separated into two classes, namely those which are osteoconductive, and those which are osteoinductive. It can be said that osteoconductive implants “conduct” bone growth across defects when implanted into osseous tissue. Osteoinductive implants, on the other hand, have the ability to “induce” cells in the area to generate bone of their own accord. These osteoinductive implants will cause the generation of bone even when they are implanted into non-osseous tissue.
- Allograft bone is a logical substitute for autologous bone. It is readily available and precludes the surgical complications and patient morbidity associated with autologous bone as noted above. Allograft bone is essentially a collagen fiber reinforced hydroxyapatite matrix containing active bone morphogenic proteins (BMP) and can be provided in a sterile form.
- BMP bone morphogenic proteins
- Demineralized Bone Matrix was first described by Senn in 1889. It was rediscovered and thoroughly studied by Urist and Strates in the late 1960's. It has since become a major product of tissue banks around the world. As the name implies, it is bone which has been demineralized by treatment with acid. The demineralized form of allograft bone is naturally both osteoinductive and osteoconductive. The demineralized allograft bone tissue is fully incorporated in the patient's tissue by a well established biological mechanism. It has been used for many years in bone surgery to fill the osseous defects previously discussed.
- Demineralized allograft bone is usually available in a lyophilized or freeze dried and sterile form to provide for extended shelf life.
- the bone in this form is usually very coarse and dry and is difficult to manipulate by the surgeon.
- One solution to use such freeze dried bone has been provided in the form of a gel, GRAFTON®, a registered trademark of Osteotech Inc., which is a simple mixture of glycerol and lyophilized, demineralized bone powder of a particle size in the range of 0.1 cm to 1.2 cm (1000 microns to 12,000 microns) as is disclosed in U.S. Pat. No. 5,073,373. GRAFTON works well to allow the surgeon to place the allograft bone material at the site.
- the carrier glycerol has a very low molecular weight (92 Daltons) and is very soluble in water, the primary component of the blood which flows at the surgical site. Glycerol also experiences a marked reduction in viscosity when its temperature rises from room temperature (typically 22° C. in an operating room) to the temperature of the patient's tissue, typically 37° C. This combination of high water solubility and reduced viscosity causes the allograft bone material with a glycerol carrier to be runny and to flow away from the site almost immediately after placement which prevents the proper retention of the bone material within the site as carefully placed by the surgeon.
- room temperature typically 22° C. in an operating room
- This combination of high water solubility and reduced viscosity causes the allograft bone material with a glycerol carrier to be runny and to flow away from the site almost immediately after placement which prevents the proper retention of the bone material within the site as carefully placed by the surgeon.
- U.S. Pat. No. 5,290,558 discloses a flowable demineralized bone powder composition using an osteogenic bone powder with large particle size ranging from about 0.1 to about 1.2 cm mixed with a low molecular weight polyhydroxy compound possessing from 2 to about 18 carbons including a number of classes of different compounds such as monosaccharides, disaccharides, water dispersible oligosaccharides and polysaccharides.
- U.S. Pat. No. 5,356,629 discloses making a rigid composition in the nature of a bone cement to fill defects in bone by mixing biocompatible particles preferably polymethylmethacrylate coated with polyhydroxyethylmethacrylate in a matrix selected from a group which lists hyaluronic acid to obtain a molded semi-solid mass which can be suitably worked for implantation into bone.
- the hyaluronic acid can also be utilized in monomeric form or in polymeric form preferably having a molecular weight not greater than about one million Daltons.
- the nonbioabsorbable material which can be used to form the biocompatible particles can be derived from xenograft bone, homologous bone, autogenous bone as well as other materials.
- the bioactive substance can also be an osteogenic agent such as demineralized bone powder, in addition to morselized cancellous bone, aspirated bone marrow and other autogenous bone sources.
- the average size of the particles employed is preferably about 0.1 to about 3.0 mm, more preferably about 0.2 to about 1.5 mm, and most preferably about 0.3 to about 1.0mm. It is inferentially mentioned but not taught that particles having average sizes of about 7,000 to 8,000 microns, or even as small as about 100 to 700 microns can be used. This is simply a cement used for implantation of hip prosthesis and is not used to promote bone growth.
- U.S. Pat. No. 6,437,018 issued Aug. 20, 2002 owned by the assignee of the present invention discloses a malleable bone putty and a flowable gel composition for application to a bone defect site to promote new bone growth at the site using demineralized lyophilized allograft bone powder.
- the bone powder has a particle size ranging from about 100 to about 850 microns and is mixed in a high molecular weight hydrogel carrier containing a sodium phosphate saline buffer, the hydrogel component of the carrier ranging from about 0.75 to 4.5% of the composition and having a molecular weight of about at least 160,000 Daltons.
- the composition has a pH between 6.8-7.4, contains about 25% to about 35% bone powder and can be additionally provided with BNP's.
- Another malleable bone putty is disclosed in U.S. Pat. No. 6,030,635, now RE 38,522, issued Feb. 29, 2000.
- inorganic materials to provide a matrix for new bone to grow at the surgical site.
- These inorganic materials include hydroxyapatite obtained from sea coral or derived synthetically. Either form may be mixed with the patient's blood and/or bone marrow to form a gel or a putty. Calcium sulfate or plaster of Paris may be mixed with water to similarly form a putty.
- Other products within this group include ceramics such as tricalcium phosphate.
- Bioglass® and other bioactive glass is a bone grafting material composed of SiO 2 , Na 2 O, CaO, P 2 O 5 glass which has the ability to produce a bio-active surface layer of hydroxyapatite carbonate within minutes of implantation.
- This material does not rely on donor availability and overcomes cultural and religious qualms or prohibitions about using human bone. Furthermore, the material has osteoinductive and osteoconductive characteristics and a long shelf life which allow it to be successfully used as bone implant repair material.
- the subject formulation is a specific mixture of bioactive glass particles and powder mixed in a carrier of glycerol and polyethylene glycol.
- An inventive aspect of this composition is overcoming handling problems while preserving a favorable biologic response by controlling the particle size of the glass particles and the weight percentage in the composition by mixing the same in the biocompatible carrier.
- the favorable handling characteristics of the putty are due to the narrow range of the percentage of glass weight in the composition and the carrier composition.
- Glass particle sizes that are larger than those of the present invention create a putty with a gritty feel which is unacceptable to a surgeon and cannot be effectively used in a syringe.
- Smaller glass particle sizes create a putty with an unfavorable biologic response because the small particles under 20 ⁇ m can be absorbed too quickly and lose their efficacy, could cause an immunological response, and could migrate though the lymphatic system.
- composition is ready to use out of the package and requires no mixing.
- FIG. 1 shows a chart reflecting a series of putty samples which were tested prior to gamma radiation sterilization
- FIG. 2 shows a chart reflecting testing of the samples of FIG. 1 before and after sterilization with gamma radiation.
- the present invention is directed towards a bioactive glass particle based putty composition mixed in a glycerol and polyethylene glycol carrier which is applied to bone defects.
- the carrier degrades in less than three days after implant to expose the bioactive glass particles for osteostimulatory bone healing.
- the particle size of glass particles when mixed with high molecular weight carrier of glycerol and polyethylene glycol carrier produces clinically useful bone inducing properties. It should be noted that when glycerol and polyethylene glycol were used separately as the carrier that the moldability and shape holding ability of the composition was inferior to that of the present composition.
- the formability property of the combined carrier and bioactive glass weight and size permits the surgeon to shape the composition to exactly fit the surgical defect. Manipulation of the lump of formable bioactive glass composition may be done without it sticking to the gloves of the surgeon, behaving somewhat like a wet clay used in sculpting.
- the implant matrix must remain at the wound site and not be washed away by the flowing blood and other irrigation fluids brought to the site by the healing mechanism. While viscous, the glycerol and polyethylene glycol carrier is a high molecular weight macromolecule and is not readily dissolved and washed away by the blood and fluids at the wound site but does degrade rapidly within the defect site to expose the bioactive glass for osteostimulatory bone healing.
- the therapeutic formable bioactive glass composition will not be dissipated by being washed away and will be present at the defect site to be osteoconductive and osteoinductive.
- the amount of bioactive glass is maximized to achieve the optimum balance of osteoconductivity and physical handling properties. Adding too much bioactive glass may create a gritty or sandy condition in which the composition is not enclosed by the surrounding viscous matrix and the glass particles are not held together.
- the preferred type of bioactive glass material used in the invention is 45s5 bioactive glass (Bioglass®) having a particle size ranging from 92 ⁇ m to 710 ⁇ m mixed in a ratio with bioactive glass powder having a size ranging from 32 ⁇ m to 90 ⁇ m.
- the primary role of a carrier is to serve as a delivery vehicle for the bioactive glass.
- the bulk viscosity of the carrier achieves the design goal of good handling properties by balancing the molecular weight and concentration used in the formulation.
- the putty is preferably formulated with a weight ranging from 68% to 76% bioactive glass particles w/w (preferably about 68% to about 70%) comprising a combination of glass particles manufactured by Novabone Inc. ranging in size from 90 ⁇ m to 710 ⁇ m mixed with glass powder also manufactured by Novabone Inc. ranging in size from 32 ⁇ m to 90 ⁇ m in a ratio from 3:5 to about 5.0 together with a 24% to 32% (wt %) glycerol and polyethylene glycol (PEG) carrier.
- a weight ranging from 68% to 76% bioactive glass particles w/w (preferably about 68% to about 70%) comprising a combination of glass particles manufactured by Novabone Inc. ranging in size from 90 ⁇ m to 710 ⁇ m mixed with glass powder also manufactured by Novabone Inc. ranging in size from 32 ⁇ m to 90 ⁇ m in a ratio from 3:5 to about 5.0 together with a 24% to 32% (wt %) glycerol and polyethylene glycol
- the ratio of glycerol to PEG preferably runs from 35:65 to 60:40; (preferably about 45:55 to about 50:50) with the total carrier ranging from about 24% to about 32% (preferably about 30% to about 32%) by weight of the composition. Particles less than 20 microns are undesirable because they can cause an inflammatory response and the small particles can migrate through the lymphatic system.
- the PEG was melted in a water bath and then mixed with glycerol.
- Additives which are beneficial to bone growth and which are additionally added into the formable composition are living cells and cell elements such as chondrocytes, red blood cells, white blood cells, platelets, blood plasma, bone marrow cells, mesenchymal stem cells, pluripotential cells, osteoblasts, osteoclasts, and fibroblasts, epithelial cells, and endothelial cells. These cells or cell elements or combinations of the same are present at a concentration of 10 5 to 10 8 per cc of carrier and are added into the composition at time of surgery.
- Growth factor additives which can be used in the present invention either at the time of packaging or at surgery depending on the stability of the growth factor are transforming growth factor (TGF-beta), insulin growth factor (IGF-1); platelet derived growth factor (PDGF), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) (numbers 1-23) and variants thereof, osteopontin, growth hormones such as somatotropin cellular attractants and attachment agents and bone morphogenic proteins (BMP's). Fiberblast growth factor is added in the amount of 2 to 4 milligrams per 10 cc of carrier solution.
- TGF-beta transforming growth factor
- IGF-1 insulin growth factor
- PDGF platelet derived growth factor
- VEGF vascular endothelial growth factor
- FGF fibroblast growth factor
- BMP's bone morphogenic proteins
- Any number of medically useful substances can be used in the invention by adding the substances to the composition at any steps in the mixing process or directly to the final composition.
- Such substances include Type I collagen and insoluble collagen derivatives for blood vessel formation and/or bone formation, hydroxyapatite, and soluble solids and/or liquids dissolved therein.
- antiviricides such as those effective against HIV and hepatitis
- antimicrobial and/or antibiotics such as erythromycin, bacitracin, neomycin, penicillin, polymyxin B, tetracycline, viomycin, chloromycetin and streptomycin, cefazolin, ampicillin, azactam, tobramycin, clindamycin and gentamycin.
- additives which can be added to the composition are amino acids, peptides, vitamins, co-factors for protein synthesis; hormones; endocrine tissue or tissue fragments; synthesizers; enzymes such as collagenase, peptidases, oxidases; polymer cell scaffolds with parenchymal cells; angiogenic drugs and polymeric carriers containing such drugs; collagen lattices; biocompatible surface active agents, antigenic agents; cytoskeletal agents; cartilage fragments.
- GAGs glycosaminoglycans
- proteoglycans to further improve and speed bone formation
- carboxymethylcellulose could be added to the formulation to provide additional elasticity to the putty for improved handling or other surgical applications.
- compositions were formulated to determine initial product usefulness. These compositions were not sterilized by gamma radiation:
- a putty composition was formulated by mixing 6.5 g of bioactive glass particles (90 ⁇ m to 710 ⁇ m) (65% w) and 1 g of bioactive glass powder (32 ⁇ m to 90 ⁇ m) (10% w) with 2.5 g of carrier (25% w) made up of glycerol and PEG having a molecular weight of 2000 in a ratio of 50:50.
- the composition had a total glass percentage (75% w) forming a putty which was very sticky and unacceptable.
- a putty composition was formulated by mixing 6.5 g of bioactive glass particles (90 ⁇ m to 710 ⁇ m) (57% w) and 2.5 g of bioactive glass powder (32 ⁇ m to 90 ⁇ m) (22% w) with 2.5 g of carrier (22% w) made up of glycerol and PEG having a molecular weight of 1500 in a ratio of 50:50.
- the composition had a total glass percentage (79% w) forming a putty which was dry and grainy and unacceptable.
- a putty composition was formulated by mixing 6.5 g of bioactive glass particles (90 ⁇ m to 710 ⁇ m) (62% w) and 1.5 g of bioactive glass powder (32 ⁇ m to 90 ⁇ m) (14% w) with 2.4 g of carrier (24% w) made up of glycerol and PEG having a molecular weight of 2000 in a ratio of 60:40.
- the composition had a total glass percentage (76% w) forming a putty which was acceptable.
- a putty composition was formulated by mixing 6.5 g of bioactive glass particles (90 ⁇ m to 710 ⁇ m) (62% w) and 1.5 g of bioactive glass powder (32 ⁇ m to 90 ⁇ m) (14% w) with 3.0 g of carrier (27% w) made up of glycerol and PEG having a molecular weight of 1500 in a ratio of 60:40.
- the composition had a total glass percentage (76% w) forming a putty which was good and acceptable.
- a putty composition was formulated by mixing 6.5 g of bioactive glass particles (90 ⁇ m to 710 ⁇ m) (62% w) and 1.5 g of bioactive glass powder (32 ⁇ m to 90 ⁇ m) (14% w) with 3.0 g of carrier (27% w) made up of glycerol and PEG having a molecular weight of 2000 in a ratio of 70:30.
- the composition had a total glass percentage (76% w) forming a putty which was tacky and unacceptable.
- a putty composition was formulated by mixing 6.5 g of bioactive glass particles (90 ⁇ m to 710 ⁇ m) (62% w) and 1.5 g of bioactive glass powder (32 ⁇ m to 90 ⁇ m) powder (14% w) with 3.0 g of carrier (27% w) made up of glycerol and PEG having a molecular weight of 1500 in a ratio of 70:30.
- the composition had a total glass percentage (76% w) forming a putty which was tacky and unacceptable.
- a putty composition was formulated by mixing 6.0 g of bioactive glass particles (90 ⁇ m to 710 ⁇ m) (57% w) and 1.5 g of bioactive glass powder (32 ⁇ m to 90 ⁇ m) (14% w) with 3.0 g of carrier (29% w) made up of glycerol and PEG having a molecular weight of 1500 in a ratio of 65:35.
- the composition had a total glass percentage (71% w) forming a putty which was grainy and unacceptable.
- a putty composition was formulated by mixing 5.5 g of bioactive glass particles (90 ⁇ m to 710 ⁇ m) (53% w) and 2.0 g of bioactive glass powder (32 ⁇ m to 90 ⁇ m) (19% w) with 3.0 g of carrier (30% w) made up of glycerol and PEG having a molecular weight of 1500 in a ratio of 65:35.
- the composition had a total glass percentage (71% w) forming a putty which was good and acceptable.
- a putty composition was formulated by mixing 6.0 g of bioactive glass particles (90 ⁇ m to 710 ⁇ m) (56% w) and 1.8 g of bioactive glass powder (32 ⁇ m to 90 ⁇ m) (17% w) with 3.0 g of carrier (28% w) made up of glycerol and PEG having a molecular weight of 2000 in a ratio of 65:35.
- the composition had a total glass percentage (73% w) forming a putty which was grainy and unacceptable.
- a putty composition was formulated by mixing 5.5 g of bioactive glass particles (90 ⁇ m to 710 ⁇ m) (51% w) and 1.9 g of bioactive glass powder (32 ⁇ m to 90 ⁇ m) (17% w) with 3.5 g of carrier (32% w) made up of glycerol and PEG having a molecular weight of 2000 in a ratio of 65:35.
- the composition had a total glass percentage (68% w) forming a putty which was very good and acceptable.
- FIG. 1 Another series of formulated putty samples which were subjected to gamma radiation sterilization were tested as can be seen in FIG. 1 .
- the testing took place on 15 samples having a carrier weight of 30% to 32% with a carrier composition ratio ranging from about 45% glycerol to about 55% PEG 2000 (11 samples; #1-9, 12 and 13); 35% glycerol to 65% PEG 2000 (1 sample, #10); 70% glycerol to 30% PEG 2000 (1 sample, #11); 50% glycerol to 50% PEG 2000 (1 sample, #14) and 40% glycerol to 60% PEG 2000 (1 sample #15).
- the glass particles (90 ⁇ m to 710 ⁇ m) ranged from 51% to 61% in total weight and glass powder (32 ⁇ m to 90 ⁇ m) ranged from 8% to 18%.
- Samples #1-6 were firm, moldable and held to shape well (note sample #1 was the nominal sample); samples #7-9 were softer than those of the nominal sample but acceptable. Sample #10 was stiff to firm and not acceptable; sample #11 was not moldable at all and samples #12, 13 and 15 were softer than the nominal (sample #1) but acceptable and sample #14 was the best putty being very soft and moldable.
- the putty mixture was then subjected to gamma sterilization of 30 + or ⁇ 5 kGy.
- the gamma radiation sterilization did not affect the performance of the glass (osteoinductiveness) unlike that of bone when it is radiated so that the osteostimulatory properties of the same are not changed.
- the gamma radiation does, however, change the handling properties of the putty making it softer as can be seen by the chart of FIG. 2 . This is believed to occur, because the gamma radiation cleaves the PEG molecules lowering its molecular weight and reducing its melting temperature. This softening was quantified by measuring permeation. It should also be noted that there were slight changes in the pH after treatment.
- the resultant putty composition preferably had 68% to 70% bioglass by weight with the carrier ranging from 30% to 32% by weight.
Abstract
The invention is directed toward a sterile formable implant composition for application to a bone defect site comprising bioactive glass particles in an aqueous carrier solution, the bioactive glass particles being added to a viscous carrier at a concentration ranging from about 68% to about 76% (w/w), the carrier comprising a mixture of glycerol and polyethylene glycol ranging from 24% to 32% (w/w) with the ratio of glycerol to polyethylene glycol ranging from about 45:55 to about 65:35.
Description
- There is no related application.
- Not applicable.
- None.
- 1. Field of Invention
- The present invention is generally directed toward a surgical bioactive glass bone implant product and more specifically is a moldable and shapeable putty composition sterilized by gamma radiation for filling bone defects having a bioactive glass material with a size ranging from 32 to 710 μm with a weight ranging from 68% to 76% by weight of the composition mixed in a fluid carrier of glycerol and polyethylene glycol.
- 2. Background of the Invention
- Surgical implants should be designed to be biocompatible in order to successfully perform their intended function. Biocompatibility may be defined as the characteristic of an implant acting in such a way as to allow its therapeutic function to be manifested without secondary adverse affects such as toxicity, foreign body reaction or cellular disruption.
- Formable compositions are used to correct surgical defects that may be caused by trauma, pathological disease, surgical intervention or other situations where defects need to be managed in osseous surgery. It is important to have the defect filler in the form of a stable, viscous formable composition to facilitate the placement of the composition into the surgical site which is usually uneven in shape and depth. The surgeon will take the composition on a spatula or other instrument and trowel it into the site or take it in his/her fingers to shape the bone defect material into the proper configuration to fit the site being corrected. It is also important that the defect filler be biocompatible.
- Osteogenic bone grafting materials may generally be separated into two classes, namely those which are osteoconductive, and those which are osteoinductive. It can be said that osteoconductive implants “conduct” bone growth across defects when implanted into osseous tissue. Osteoinductive implants, on the other hand, have the ability to “induce” cells in the area to generate bone of their own accord. These osteoinductive implants will cause the generation of bone even when they are implanted into non-osseous tissue.
- Many products have been developed in an attempt to treat this surgical need for a biocompatible formable material. One such example is autologous bone particles or segments recovered from the patient. When removed from the patient, the segments or bone particles are wet and viscous from the associated blood. This works very well to heal the defect but requires significant secondary surgery resulting in lengthening the surgery, extending the time the patient is under anesthesia and increasing the cost. In addition, a significant increase in patient morbidity is attendant in this technique as the surgeon must take bone from a non-involved site in the patient to recover sufficient healthy bone, marrow and blood to perform the defect filling surgery. This leads to significant post-operative pain.
- Allograft bone is a logical substitute for autologous bone. It is readily available and precludes the surgical complications and patient morbidity associated with autologous bone as noted above. Allograft bone is essentially a collagen fiber reinforced hydroxyapatite matrix containing active bone morphogenic proteins (BMP) and can be provided in a sterile form.
- Demineralized Bone Matrix (DBM) was first described by Senn in 1889. It was rediscovered and thoroughly studied by Urist and Strates in the late 1960's. It has since become a major product of tissue banks around the world. As the name implies, it is bone which has been demineralized by treatment with acid. The demineralized form of allograft bone is naturally both osteoinductive and osteoconductive. The demineralized allograft bone tissue is fully incorporated in the patient's tissue by a well established biological mechanism. It has been used for many years in bone surgery to fill the osseous defects previously discussed.
- Demineralized allograft bone is usually available in a lyophilized or freeze dried and sterile form to provide for extended shelf life. The bone in this form is usually very coarse and dry and is difficult to manipulate by the surgeon. One solution to use such freeze dried bone has been provided in the form of a gel, GRAFTON®, a registered trademark of Osteotech Inc., which is a simple mixture of glycerol and lyophilized, demineralized bone powder of a particle size in the range of 0.1 cm to 1.2 cm (1000 microns to 12,000 microns) as is disclosed in U.S. Pat. No. 5,073,373. GRAFTON works well to allow the surgeon to place the allograft bone material at the site.
- However, the carrier, glycerol has a very low molecular weight (92 Daltons) and is very soluble in water, the primary component of the blood which flows at the surgical site. Glycerol also experiences a marked reduction in viscosity when its temperature rises from room temperature (typically 22° C. in an operating room) to the temperature of the patient's tissue, typically 37° C. This combination of high water solubility and reduced viscosity causes the allograft bone material with a glycerol carrier to be runny and to flow away from the site almost immediately after placement which prevents the proper retention of the bone material within the site as carefully placed by the surgeon.
- U.S. Pat. No. 5,290,558 discloses a flowable demineralized bone powder composition using an osteogenic bone powder with large particle size ranging from about 0.1 to about 1.2 cm mixed with a low molecular weight polyhydroxy compound possessing from 2 to about 18 carbons including a number of classes of different compounds such as monosaccharides, disaccharides, water dispersible oligosaccharides and polysaccharides.
- U.S. Pat. No. 5,356,629 discloses making a rigid composition in the nature of a bone cement to fill defects in bone by mixing biocompatible particles preferably polymethylmethacrylate coated with polyhydroxyethylmethacrylate in a matrix selected from a group which lists hyaluronic acid to obtain a molded semi-solid mass which can be suitably worked for implantation into bone. The hyaluronic acid can also be utilized in monomeric form or in polymeric form preferably having a molecular weight not greater than about one million Daltons. It is noted that the nonbioabsorbable material which can be used to form the biocompatible particles can be derived from xenograft bone, homologous bone, autogenous bone as well as other materials. The bioactive substance can also be an osteogenic agent such as demineralized bone powder, in addition to morselized cancellous bone, aspirated bone marrow and other autogenous bone sources. The average size of the particles employed is preferably about 0.1 to about 3.0 mm, more preferably about 0.2 to about 1.5 mm, and most preferably about 0.3 to about 1.0mm. It is inferentially mentioned but not taught that particles having average sizes of about 7,000 to 8,000 microns, or even as small as about 100 to 700 microns can be used. This is simply a cement used for implantation of hip prosthesis and is not used to promote bone growth.
- U.S. Pat. No. 6,437,018 issued Aug. 20, 2002 owned by the assignee of the present invention discloses a malleable bone putty and a flowable gel composition for application to a bone defect site to promote new bone growth at the site using demineralized lyophilized allograft bone powder. The bone powder has a particle size ranging from about 100 to about 850 microns and is mixed in a high molecular weight hydrogel carrier containing a sodium phosphate saline buffer, the hydrogel component of the carrier ranging from about 0.75 to 4.5% of the composition and having a molecular weight of about at least 160,000 Daltons. The composition has a pH between 6.8-7.4, contains about 25% to about 35% bone powder and can be additionally provided with BNP's. Another malleable bone putty is disclosed in U.S. Pat. No. 6,030,635, now RE 38,522, issued Feb. 29, 2000.
- Another product group involves the use of inorganic materials to provide a matrix for new bone to grow at the surgical site. These inorganic materials include hydroxyapatite obtained from sea coral or derived synthetically. Either form may be mixed with the patient's blood and/or bone marrow to form a gel or a putty. Calcium sulfate or plaster of Paris may be mixed with water to similarly form a putty. Other products within this group include ceramics such as tricalcium phosphate.
- The use of ceramic compositions utilizing beta tricalcium phosphate and alpha tricalcium phosphate (TCP) for bone graft substitutes are also well known the art. These graft materials generally harden in place. U.S. Pat. No. 5,522,893 issued Jun. 4, 1996 discloses a bone filling material which is a combination of tricalcium phosphate and dicalcium phosphate salts that are mixed and react to harden and form hydroxycarbonate apatite after implantation. The prior art TCP compositions tend to harden rather quickly and have short if any shelf life. Thus, the composition has to be mixed at the time of surgery or in a short time period before the time of surgery.
- Bioglass® and other bioactive glass is a bone grafting material composed of SiO2, Na2O, CaO, P2O5 glass which has the ability to produce a bio-active surface layer of hydroxyapatite carbonate within minutes of implantation. This material does not rely on donor availability and overcomes cultural and religious qualms or prohibitions about using human bone. Furthermore, the material has osteoinductive and osteoconductive characteristics and a long shelf life which allow it to be successfully used as bone implant repair material.
- The subject formulation is a specific mixture of bioactive glass particles and powder mixed in a carrier of glycerol and polyethylene glycol.
- An inventive aspect of this composition is overcoming handling problems while preserving a favorable biologic response by controlling the particle size of the glass particles and the weight percentage in the composition by mixing the same in the biocompatible carrier. The favorable handling characteristics of the putty are due to the narrow range of the percentage of glass weight in the composition and the carrier composition. Glass particle sizes that are larger than those of the present invention create a putty with a gritty feel which is unacceptable to a surgeon and cannot be effectively used in a syringe. Smaller glass particle sizes create a putty with an unfavorable biologic response because the small particles under 20 μm can be absorbed too quickly and lose their efficacy, could cause an immunological response, and could migrate though the lymphatic system.
- It is an object of the invention to utilize a bioactive glass defect material having a particle size that is useful to achieve the malleability characteristics of a putty composition in that it holds shape and does not melt during handling which results in easy application allowing easy insertion by the surgeon into the bone defect area.
- It is also an object of the invention to create a bioactive glass defect repair material which can be easily handled by the physician and maintains integrity after the implant until the surgical site is closed and stays in place during irrigation.
- It is another object of the invention that the composition is ready to use out of the package and requires no mixing.
- It is another object of the invention to utilize a carrier which degrades rapidly to expose the bioactive glass for osteostimulatory bone healing.
- It is still another object of the invention to create a bioactive glass defect material repair which is stable and has an extended shelf life of two years when packaged.
- It is another object of the invention to create a bioactive glass defect repair material which additionally uses cellular material such as living cells and cell elements.
- It is yet another object of the invention to use a growth factor in the bioactive glass defect repair material.
- It is still another object of the invention to use an anti-infective agent in the bioactive glass defect repair material.
- These and other objects, advantages, and novel features of the present invention will become apparent when considered with the teachings contained in the detailed disclosure along with the accompanying drawings.
-
FIG. 1 shows a chart reflecting a series of putty samples which were tested prior to gamma radiation sterilization; and -
FIG. 2 shows a chart reflecting testing of the samples ofFIG. 1 before and after sterilization with gamma radiation. - The present invention is directed towards a bioactive glass particle based putty composition mixed in a glycerol and polyethylene glycol carrier which is applied to bone defects. The carrier degrades in less than three days after implant to expose the bioactive glass particles for osteostimulatory bone healing.
- The particle size of glass particles when mixed with high molecular weight carrier of glycerol and polyethylene glycol carrier produces clinically useful bone inducing properties. It should be noted that when glycerol and polyethylene glycol were used separately as the carrier that the moldability and shape holding ability of the composition was inferior to that of the present composition. The formability property of the combined carrier and bioactive glass weight and size permits the surgeon to shape the composition to exactly fit the surgical defect. Manipulation of the lump of formable bioactive glass composition may be done without it sticking to the gloves of the surgeon, behaving somewhat like a wet clay used in sculpting.
- It is an important aspect of the present invention that the implant matrix must remain at the wound site and not be washed away by the flowing blood and other irrigation fluids brought to the site by the healing mechanism. While viscous, the glycerol and polyethylene glycol carrier is a high molecular weight macromolecule and is not readily dissolved and washed away by the blood and fluids at the wound site but does degrade rapidly within the defect site to expose the bioactive glass for osteostimulatory bone healing.
- Thus, the therapeutic formable bioactive glass composition will not be dissipated by being washed away and will be present at the defect site to be osteoconductive and osteoinductive. The amount of bioactive glass is maximized to achieve the optimum balance of osteoconductivity and physical handling properties. Adding too much bioactive glass may create a gritty or sandy condition in which the composition is not enclosed by the surrounding viscous matrix and the glass particles are not held together. The preferred type of bioactive glass material used in the invention is 45s5 bioactive glass (Bioglass®) having a particle size ranging from 92 μm to 710 μm mixed in a ratio with bioactive glass powder having a size ranging from 32 μm to 90 μm.
- The primary role of a carrier is to serve as a delivery vehicle for the bioactive glass. The bulk viscosity of the carrier achieves the design goal of good handling properties by balancing the molecular weight and concentration used in the formulation.
- The putty is preferably formulated with a weight ranging from 68% to 76% bioactive glass particles w/w (preferably about 68% to about 70%) comprising a combination of glass particles manufactured by Novabone Inc. ranging in size from 90 μm to 710 μm mixed with glass powder also manufactured by Novabone Inc. ranging in size from 32 μm to 90 μm in a ratio from 3:5 to about 5.0 together with a 24% to 32% (wt %) glycerol and polyethylene glycol (PEG) carrier. The ratio of glycerol to PEG preferably runs from 35:65 to 60:40; (preferably about 45:55 to about 50:50) with the total carrier ranging from about 24% to about 32% (preferably about 30% to about 32%) by weight of the composition. Particles less than 20 microns are undesirable because they can cause an inflammatory response and the small particles can migrate through the lymphatic system.
- In the present formulation, a range of 68% to 70% bioactive glass was the most preferred range with being selected as the optimum glass material weight formulation. A one week accelerated aging study was performed at 40° C. (equivalent to 4 weeks at ambient temperatures) on the putty composition and there was no change in the putty. The penetration, pH and handling of the preferred putty did not change from time zero to one week accelerated aging.
- 1. Novabone 45s5 bioactive glass (SiO2Na2OCaOP2O5) 90 μm to 710 μm in size manufactured by Novabone Products LLC. The composition by weight is:
-
SiO2 45% Na2O 24.5% CaO 24.5% P2O5 6.0%
with a tolerance of about ±2.0%. It has a density of 2.73 grams/cc and a softening point of 627° C. - 2. Novabone 45s5 bioactive glass power (SiO2Na2OCaOP2O5) 32 μm to 90 μm in size sieved to remove powder less than 32 μm.
- 3. Glycerol manufactured by EMD Chemicals, Inc.
- 4. Polyethylene glycol (PEG) manufactured by Clariant Corporation having a molecular weight ranging from 1000 to 2000 Daltons, preferably 1500 and 2000 Daltons.
- The PEG was melted in a water bath and then mixed with glycerol.
- Additives which are beneficial to bone growth and which are additionally added into the formable composition are living cells and cell elements such as chondrocytes, red blood cells, white blood cells, platelets, blood plasma, bone marrow cells, mesenchymal stem cells, pluripotential cells, osteoblasts, osteoclasts, and fibroblasts, epithelial cells, and endothelial cells. These cells or cell elements or combinations of the same are present at a concentration of 105 to 108 per cc of carrier and are added into the composition at time of surgery.
- Growth factor additives which can be used in the present invention either at the time of packaging or at surgery depending on the stability of the growth factor are transforming growth factor (TGF-beta), insulin growth factor (IGF-1); platelet derived growth factor (PDGF), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) (numbers 1-23) and variants thereof, osteopontin, growth hormones such as somatotropin cellular attractants and attachment agents and bone morphogenic proteins (BMP's). Fiberblast growth factor is added in the amount of 2 to 4 milligrams per 10 cc of carrier solution.
- Any number of medically useful substances can be used in the invention by adding the substances to the composition at any steps in the mixing process or directly to the final composition. Such substances include Type I collagen and insoluble collagen derivatives for blood vessel formation and/or bone formation, hydroxyapatite, and soluble solids and/or liquids dissolved therein.
- Also included in the additives which may be added to the carrier are antiviricides such as those effective against HIV and hepatitis; antimicrobial and/or antibiotics such as erythromycin, bacitracin, neomycin, penicillin, polymyxin B, tetracycline, viomycin, chloromycetin and streptomycin, cefazolin, ampicillin, azactam, tobramycin, clindamycin and gentamycin.
- It is also envisioned that other additives which can be added to the composition are amino acids, peptides, vitamins, co-factors for protein synthesis; hormones; endocrine tissue or tissue fragments; synthesizers; enzymes such as collagenase, peptidases, oxidases; polymer cell scaffolds with parenchymal cells; angiogenic drugs and polymeric carriers containing such drugs; collagen lattices; biocompatible surface active agents, antigenic agents; cytoskeletal agents; cartilage fragments.
- Food (glucose) for the cells noted above could be added along with amino acids. It is also envisioned that one could add additional glycosaminoglycans (GAGs) or proteoglycans to further improve and speed bone formation (the specific GAGs of physiological significance are hyaluronic acid, dermatan sulfate, chondroitin sulfate, heparin, heparan sulfate, and keratan sulfate). In addition, carboxymethylcellulose could be added to the formulation to provide additional elasticity to the putty for improved handling or other surgical applications.
- In the following examples, various compositions were formulated to determine initial product usefulness. These compositions were not sterilized by gamma radiation:
- A putty composition was formulated by mixing 6.5 g of bioactive glass particles (90 μm to 710 μm) (65% w) and 1 g of bioactive glass powder (32 μm to 90 μm) (10% w) with 2.5 g of carrier (25% w) made up of glycerol and PEG having a molecular weight of 2000 in a ratio of 50:50. The composition had a total glass percentage (75% w) forming a putty which was very sticky and unacceptable.
- A putty composition was formulated by mixing 6.5 g of bioactive glass particles (90 μm to 710 μm) (57% w) and 2.5 g of bioactive glass powder (32 μm to 90 μm) (22% w) with 2.5 g of carrier (22% w) made up of glycerol and PEG having a molecular weight of 1500 in a ratio of 50:50. The composition had a total glass percentage (79% w) forming a putty which was dry and grainy and unacceptable.
- A putty composition was formulated by mixing 6.5 g of bioactive glass particles (90 μm to 710 μm) (62% w) and 1.5 g of bioactive glass powder (32 μm to 90 μm) (14% w) with 2.4 g of carrier (24% w) made up of glycerol and PEG having a molecular weight of 2000 in a ratio of 60:40. The composition had a total glass percentage (76% w) forming a putty which was acceptable.
- A putty composition was formulated by mixing 6.5 g of bioactive glass particles (90 μm to 710 μm) (62% w) and 1.5 g of bioactive glass powder (32 μm to 90 μm) (14% w) with 3.0 g of carrier (27% w) made up of glycerol and PEG having a molecular weight of 1500 in a ratio of 60:40. The composition had a total glass percentage (76% w) forming a putty which was good and acceptable.
- A putty composition was formulated by mixing 6.5 g of bioactive glass particles (90 μm to 710 μm) (62% w) and 1.5 g of bioactive glass powder (32 μm to 90 μm) (14% w) with 3.0 g of carrier (27% w) made up of glycerol and PEG having a molecular weight of 2000 in a ratio of 70:30. The composition had a total glass percentage (76% w) forming a putty which was tacky and unacceptable.
- A putty composition was formulated by mixing 6.5 g of bioactive glass particles (90 μm to 710 μm) (62% w) and 1.5 g of bioactive glass powder (32 μm to 90 μm) powder (14% w) with 3.0 g of carrier (27% w) made up of glycerol and PEG having a molecular weight of 1500 in a ratio of 70:30. The composition had a total glass percentage (76% w) forming a putty which was tacky and unacceptable.
- A putty composition was formulated by mixing 6.0 g of bioactive glass particles (90 μm to 710 μm) (57% w) and 1.5 g of bioactive glass powder (32 μm to 90 μm) (14% w) with 3.0 g of carrier (29% w) made up of glycerol and PEG having a molecular weight of 1500 in a ratio of 65:35. The composition had a total glass percentage (71% w) forming a putty which was grainy and unacceptable.
- A putty composition was formulated by mixing 5.5 g of bioactive glass particles (90 μm to 710 μm) (53% w) and 2.0 g of bioactive glass powder (32 μm to 90 μm) (19% w) with 3.0 g of carrier (30% w) made up of glycerol and PEG having a molecular weight of 1500 in a ratio of 65:35. The composition had a total glass percentage (71% w) forming a putty which was good and acceptable.
- A putty composition was formulated by mixing 6.0 g of bioactive glass particles (90 μm to 710 μm) (56% w) and 1.8 g of bioactive glass powder (32 μm to 90 μm) (17% w) with 3.0 g of carrier (28% w) made up of glycerol and PEG having a molecular weight of 2000 in a ratio of 65:35. The composition had a total glass percentage (73% w) forming a putty which was grainy and unacceptable.
- A putty composition was formulated by mixing 5.5 g of bioactive glass particles (90 μm to 710 μm) (51% w) and 1.9 g of bioactive glass powder (32 μm to 90 μm) (17% w) with 3.5 g of carrier (32% w) made up of glycerol and PEG having a molecular weight of 2000 in a ratio of 65:35. The composition had a total glass percentage (68% w) forming a putty which was very good and acceptable.
- Another series of formulated putty samples which were subjected to gamma radiation sterilization were tested as can be seen in
FIG. 1 . The testing took place on 15 samples having a carrier weight of 30% to 32% with a carrier composition ratio ranging from about 45% glycerol to about 55% PEG 2000 (11 samples; #1-9, 12 and 13); 35% glycerol to 65% PEG 2000 (1 sample, #10); 70% glycerol to 30% PEG 2000 (1 sample, #11); 50% glycerol to 50% PEG 2000 (1 sample, #14) and 40% glycerol to 60% PEG 2000 (1 sample #15). The glass particles (90 μm to 710 μm) ranged from 51% to 61% in total weight and glass powder (32 μm to 90 μm) ranged from 8% to 18%. - Samples #1-6 were firm, moldable and held to shape well (note
sample # 1 was the nominal sample); samples #7-9 were softer than those of the nominal sample but acceptable.Sample # 10 was stiff to firm and not acceptable;sample # 11 was not moldable at all andsamples # sample # 14 was the best putty being very soft and moldable. - The putty mixture was then subjected to gamma sterilization of 30 + or −5 kGy. The gamma radiation sterilization did not affect the performance of the glass (osteoinductiveness) unlike that of bone when it is radiated so that the osteostimulatory properties of the same are not changed. The gamma radiation does, however, change the handling properties of the putty making it softer as can be seen by the chart of
FIG. 2 . This is believed to occur, because the gamma radiation cleaves the PEG molecules lowering its molecular weight and reducing its melting temperature. This softening was quantified by measuring permeation. It should also be noted that there were slight changes in the pH after treatment. - The resultant putty composition preferably had 68% to 70% bioglass by weight with the carrier ranging from 30% to 32% by weight.
- The principles, preferred embodiments and modes of operation of the present invention have been described in the foregoing specification. However, the invention should not be construed as limited to the particular embodiments which have been described above. Instead, the embodiments described here should be regarded as illustrative rather than restrictive. Variations and changes may be made by others without departing from the scope of the present invention as defined by the following claims:
Claims (28)
1.-21. (canceled)
22. A composition for application to a bone defect site comprising (A) bioactive glass, (B) a carrier and (C) one or more additives,
wherein said bioactive glass is present in an amount ranging from about 68% to about 76% (w/w) of the composition,
wherein the carrier comprises a mixture of glycerol and polyethylene glycol, and the carrier is present in an amount ranging from about 24% to about 32% (w/w) of the composition; in which the glycerol and polyethylene glycol are present in a ratio of glycerol to polyethylene glycol ranging from about 45:55 to about 65:35, and
wherein the one or more additives comprise bone morphogenic proteins, collagens, hydroxyapatites, amino acids, peptides, vitamins, co-factors for protein synthesis; hormones, endocrine tissues or tissue fragments; synthesizers; enzymes; polymer cell scaffolds with parenchymal cells; angiogenic drugs, polymeric carriers containing one or more drugs; collagen lattices; biocompatible surface active agents, antigenic agents; cytoskeletal agents; cartilage fragments, glucoses, glycosaminoglycans, proteoglycans, carboxymethylcelluloses, red blood cells, white blood cells, platelets, osteoclasts, endothelial cells or combinations thereof.
23. The composition of claim 22 , wherein the glycosaminoglycan comprises one or more hyaluronic acids, dermatan sulfates, chondroitin sulfates, heparins, heparin sulfates, or keratan sulfates.
24. The composition of claim 22 , wherein the enzyme comprises one or more collagenases, peptidases, or oxidases.
25. The composition of claim 22 , wherein the composition is malleable during application of the composition to the bone defect.
26. The composition of claim 22 , wherein the composition is a putty.
27. The composition of claim 22 , wherein the bioactive glass is present in an amount ranging from about 68% to about 70% (w/w) of the composition.
28. The composition of claim 22 , wherein said bioactive glass comprises units ranging in size from 32 microns to 710 microns.
29. The composition of claim 22 , wherein said bioactive glass comprises (a) glass particles and (b) glass powder, wherein said glass powder ranges from 32 μm to 90 μm in size.
30. The composition of claim 22 , wherein said bioactive glass comprises (a) glass particles wherein said glass particles range from 90 μm to 710 μm in size and (b) glass powder.
31. The composition of claim 22 , wherein said bioactive glass comprises glass particles ranging from 90 μm to 710 μm in size and glass powder ranging from 32 μm to 90 μm in size, and wherein said glass particles and said glass powder are present in a ratio of glass particles to glass powder ranging from about 3.5:1 to about 5:1.
32. The composition of claim 22 , wherein said bioactive glass comprises glass particles and glass powder, and wherein said glass particles are present in an amount ranging from about 53% to about 62% (w/w) of the composition.
33. The composition of claim 22 , wherein said bioactive glass comprises glass particles and glass powder, and wherein said glass powder is present in an amount ranging from about 12% to about 19% (w/w) of the composition.
34. The composition of claim 22 , wherein said glycerol and said polyethylene glycol are present in a ratio of glycerol to polyethylene glycol of about 50:50.
35. The composition of claim 22 , wherein said polyethylene glycol has a molecular weight ranging from 1000 to 2000 Daltons.
36. The composition of claim 22 , wherein said composition has been sterilized by gamma radiation.
37. The composition of claim 22 , further comprising one or more growth factor additives, wherein said growth factor additive comprises a transforming growth factor, an insulin growth factor, a platelet derived growth factor, a vascular endothelial growth factor, a fibroblast growth factor, osteopontin, a growth hormone, somatotropin, or combinations thereof.
38. The composition of claim 22 , further comprising one or more growth factor additives wherein said growth factor additive comprises a fibroblast growth factor, a variant thereof, or combinations thereof in an amount of 2 to 4 milligrams per 10 cc of carrier.
39. The composition of claim 22 , further comprising one or more antiviral additives, antimicrobials, antibiotics, or combinations thereof, wherein said antiviral additive comprises one or more of an antiviral additive that is effective against HIV and hepatitis, and wherein said antimicrobial or antibiotic comprises one or more of erythromycin, bacitracin, neomycin, penicillin, polymyxin B, tetracycline, viomycin, chloromycetin, streptomycin, cefazolin, ampicillin, azactam, tobramycin, clindamycin, gentamycin, or combinations thereof
40. The composition of claim 22 , further comprising living cells.
41. The composition of claim 40 , wherein the living cells comprise chondrocytes, platelets, blood plasma, bone marrow cells, mesenchymal stem cells, pluripotential cells, osteoblasts, fibroblasts, or combinations thereof.
42. The composition of claim 40 , wherein the living cells are present in an amount ranging from 105 to 108 per cc of the carrier.
43. A composition for application to a bone defect site comprising (A) bioactive glass, (B) a carrier and (C) one or more additives,
wherein said bioactive glass is present in an amount ranging from about 68% to about 76% (w/w) of the composition, and said bioactive glass comprises glass particles ranging from 90 μm to 710 μm in size,
wherein the carrier comprises a mixture of glycerol and polyethylene glycol, and the carrier is present in an amount ranging from about 24% to about 32% (w/w) of the composition, and wherein said glycerol and said polyethylene glycol are present in a ratio of glycerol to polyethylene glycol ranging from about 45:55 to about 65:35, and
wherein the one or more additives comprise bone morphogenic proteins, collagens, hydroxyapatites, amino acids, peptides, vitamins, co-factors for protein synthesis; hormones, endocrine tissues or tissue fragments; synthesizers; enzymes; polymer cell scaffolds with parenchymal cells; angiogenic drugs, polymeric carriers containing one or more drugs; collagen lattices; biocompatible surface active agents, antigenic agents; cytoskeletal agents; cartilage fragments, glucoses, glycosaminoglycans, proteoglycans, carboxymethylcelluloses, red blood cells, white blood cells, platelets, osteoclasts, endothelial cells or combinations thereof.
44. The composition of claim 43 , wherein the glycosaminoglycan comprises one or more hyaluronic acids, dermatan sulfates, chondroitin sulfates, heparins, heparin sulfates, or keratan sulfates.
45. The composition of claim 43 , wherein the enzyme comprises one or more collagenases, peptidases, or oxidases.
46. A composition for application to a bone defect site comprising (A) bioactive glass, (B) a carrier and (C) one or more additives,
wherein said bioactive glass comprises glass particles ranging from 90 μm to 710 μm in size and glass powder ranging from 32 μm to 90 μm in size, wherein said glass particles and said glass powder are present in a ratio of glass particles to glass powder ranging from about 3.5:1 to about 5:1, and wherein said bioactive glass is present in an amount ranging from about 68% to about 76% (w/w) of the composition,
wherein the carrier comprises a mixture of glycerol and polyethylene glycol, and wherein the carrier is present in an amount ranging from about 24% to about 32% (w/w) of the composition, and wherein said glycerol and said polyethylene glycol are present in a ratio of glycerol to polyethylene glycol ranging from about 45:55 to about 65:35, and
wherein the one or more additives comprise bone morphogenic proteins, collagens, hydroxyapatites, amino acids, peptides, vitamins, co-factors for protein synthesis; hormones, endocrine tissues or tissue fragments; synthesizers; enzymes; polymer cell scaffolds with parenchymal cells; angiogenic drugs, polymeric carriers containing one or more drugs; collagen lattices; biocompatible surface active agents, antigenic agents; cytoskeletal agents; cartilage fragments, glucoses, glycosaminoglycans, proteoglycans, carboxymethylcelluloses, red blood cells, white blood cells, platelets, osteoclasts, endothelial cells or combinations thereof.
47. The composition of claim 46 , wherein the glycosaminoglycan comprises one or more hyaluronic acids, dermatan sulfates, chondroitin sulfates, heparins, heparin sulfates, or keratan sulfates.
48. The composition of claim 46 , wherein the enzyme comprises one or more collagenases, peptidases, or oxidases.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/614,369 US20130011446A1 (en) | 2007-03-15 | 2012-09-13 | Ceramic composition for filling bone defects |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/724,255 US8288344B2 (en) | 2007-03-15 | 2007-03-15 | Ceramic composition for filling bone defects |
US13/614,369 US20130011446A1 (en) | 2007-03-15 | 2012-09-13 | Ceramic composition for filling bone defects |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/724,255 Continuation US8288344B2 (en) | 2007-03-15 | 2007-03-15 | Ceramic composition for filling bone defects |
Publications (1)
Publication Number | Publication Date |
---|---|
US20130011446A1 true US20130011446A1 (en) | 2013-01-10 |
Family
ID=39762946
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/724,255 Active 2030-02-16 US8288344B2 (en) | 2007-03-15 | 2007-03-15 | Ceramic composition for filling bone defects |
US13/614,369 Abandoned US20130011446A1 (en) | 2007-03-15 | 2012-09-13 | Ceramic composition for filling bone defects |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/724,255 Active 2030-02-16 US8288344B2 (en) | 2007-03-15 | 2007-03-15 | Ceramic composition for filling bone defects |
Country Status (3)
Country | Link |
---|---|
US (2) | US8288344B2 (en) |
CN (1) | CN101264340B (en) |
CA (1) | CA2582551C (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111529749A (en) * | 2020-04-15 | 2020-08-14 | 杭州憶盛医疗科技有限公司 | Regenerative medical material for promoting tissue in-situ regeneration and preparation method thereof |
US11052175B2 (en) | 2015-08-19 | 2021-07-06 | Musculoskeletal Transplant Foundation | Cartilage-derived implants and methods of making and using same |
US11198638B2 (en) | 2017-11-28 | 2021-12-14 | Corning Incorporated | Bioactive borate glass and methods thereof |
US11274059B2 (en) | 2017-11-28 | 2022-03-15 | Corning Incorporated | Bioactive glass compositions and dentin hypersensitivity remediation |
US11384009B2 (en) * | 2017-11-28 | 2022-07-12 | Corning Incorporated | High liquidus viscosity bioactive glass |
US11446410B2 (en) | 2017-11-28 | 2022-09-20 | Corning Incorporated | Chemically strengthened bioactive glass-ceramics |
US11814649B2 (en) | 2016-05-27 | 2023-11-14 | Corning Incorporated | Lithium disilicate glass-ceramic compositions and methods thereof |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI20086161A0 (en) * | 2008-12-04 | 2008-12-04 | Tampereen Yliopisto Solu Ja Ku | Biological regenerate for obliteration |
WO2011001028A1 (en) * | 2009-06-29 | 2011-01-06 | Bonalive Biomaterials Oy | A bioactive glass for use in conditions relating to bone infections |
EP2322134B1 (en) | 2009-11-12 | 2012-09-12 | BonAlive Biomaterials Oy | Implantable paste and its use |
US8673018B2 (en) | 2010-02-05 | 2014-03-18 | AMx Tek LLC | Methods of using water-soluble inorganic compounds for implants |
GB201010761D0 (en) | 2010-06-25 | 2010-08-11 | Univ Aberdeen | Bone graft system |
US9265830B2 (en) | 2011-04-20 | 2016-02-23 | Warsaw Orthopedic, Inc. | Implantable compositions and methods for preparing the same |
AU2012329012B2 (en) * | 2011-10-24 | 2016-04-07 | Synergy Biomedical Llc | Compositions and their use in bone healing |
CN102488927B (en) * | 2011-12-16 | 2013-08-21 | 成都迪康中科生物医学材料有限公司 | Bone repairing material and preparation method thereof |
US10207027B2 (en) * | 2012-06-11 | 2019-02-19 | Globus Medical, Inc. | Bioactive bone graft substitutes |
PL2875832T3 (en) | 2014-03-17 | 2016-12-30 | Implantable paste and its use | |
US9238090B1 (en) | 2014-12-24 | 2016-01-19 | Fettech, Llc | Tissue-based compositions |
EP3432939B1 (en) * | 2016-03-24 | 2024-05-01 | Heraeus Medical GmbH | Scaffolding material, methods and uses |
CN108114312A (en) * | 2018-02-26 | 2018-06-05 | 王由 | A kind of plasticity 45S5 bioactivity glass and preparation method thereof |
CN110302431A (en) * | 2019-06-21 | 2019-10-08 | 湖北联结生物材料有限公司 | A kind of injectable type bioactivity glass of the DBM containing decalcified bone matrix and its preparation method and application |
TWI764332B (en) | 2020-10-22 | 2022-05-11 | 擎睿生醫有限公司 | Bone graft composition |
CN114984307B (en) * | 2021-03-02 | 2023-08-15 | 中科硅骨(东莞)医疗器械有限公司 | Shapable bone repair material and preparation method thereof |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2651439B1 (en) * | 1989-09-06 | 1994-09-23 | Fbfc International Sa Nv | BIOREACTIVE MATERIAL FOR PROSTHESIS OR COMPOSITE IMPLANTS. |
US5073373A (en) * | 1989-09-21 | 1991-12-17 | Osteotech, Inc. | Flowable demineralized bone powder composition and its use in bone repair |
US5290558A (en) * | 1989-09-21 | 1994-03-01 | Osteotech, Inc. | Flowable demineralized bone powder composition and its use in bone repair |
US5356629A (en) * | 1991-07-12 | 1994-10-18 | United States Surgical Corporation | Composition for effecting bone repair |
US5522893A (en) * | 1993-03-12 | 1996-06-04 | American Dental Association Health Foundation | Calcium phosphate hydroxyapatite precursor and methods for making and using the same |
USRE38522E1 (en) * | 1998-02-27 | 2004-05-25 | Musculoskeletal Transplant Foundation | Malleable paste for filling bone defects |
US6030635A (en) * | 1998-02-27 | 2000-02-29 | Musculoskeletal Transplant Foundation | Malleable paste for filling bone defects |
US6437018B1 (en) * | 1998-02-27 | 2002-08-20 | Musculoskeletal Transplant Foundation | Malleable paste with high molecular weight buffered carrier for filling bone defects |
US6642285B1 (en) * | 1999-02-02 | 2003-11-04 | Robert Mathys Stiftung | Implant comprising calcium cement and hydrophobic liquid |
WO2004000374A1 (en) * | 2002-06-19 | 2003-12-31 | Dr. H.C. Robert Mathys Stiftung | Hydraulic cement based on calcium phosphate for surgical use |
WO2005034816A1 (en) * | 2003-09-23 | 2005-04-21 | Ortho Therapeutics, Llc. | Bioabsorbable putty-like hemostatic implants |
US7888119B2 (en) * | 2005-10-14 | 2011-02-15 | University Of Central Florida Research Foundation, Inc. | Tissue substitutes comprising stem cells and reduced ceria |
EP1976459A4 (en) * | 2006-01-19 | 2012-06-20 | Warsaw Orthopedic Inc | Porous osteoimplant |
US20080147197A1 (en) * | 2006-12-14 | 2008-06-19 | Mckay William F | Biodegradable osteogenic porous biomedical implant with impermeable membrane |
WO2008112157A1 (en) * | 2007-03-09 | 2008-09-18 | Jipin Zhong | Osteostimulative settable bone graft putty |
-
2007
- 2007-03-15 US US11/724,255 patent/US8288344B2/en active Active
- 2007-03-22 CA CA2582551A patent/CA2582551C/en active Active
- 2007-11-06 CN CN2007101850304A patent/CN101264340B/en active Active
-
2012
- 2012-09-13 US US13/614,369 patent/US20130011446A1/en not_active Abandoned
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11052175B2 (en) | 2015-08-19 | 2021-07-06 | Musculoskeletal Transplant Foundation | Cartilage-derived implants and methods of making and using same |
US11806443B2 (en) | 2015-08-19 | 2023-11-07 | Musculoskeletal Transplant Foundation | Cartilage-derived implants and methods of making and using same |
US11938245B2 (en) | 2015-08-19 | 2024-03-26 | Musculoskeletal Transplant Foundation | Cartilage-derived implants and methods of making and using same |
US11814649B2 (en) | 2016-05-27 | 2023-11-14 | Corning Incorporated | Lithium disilicate glass-ceramic compositions and methods thereof |
US11198638B2 (en) | 2017-11-28 | 2021-12-14 | Corning Incorporated | Bioactive borate glass and methods thereof |
US11274059B2 (en) | 2017-11-28 | 2022-03-15 | Corning Incorporated | Bioactive glass compositions and dentin hypersensitivity remediation |
US11384009B2 (en) * | 2017-11-28 | 2022-07-12 | Corning Incorporated | High liquidus viscosity bioactive glass |
US11446410B2 (en) | 2017-11-28 | 2022-09-20 | Corning Incorporated | Chemically strengthened bioactive glass-ceramics |
CN111529749A (en) * | 2020-04-15 | 2020-08-14 | 杭州憶盛医疗科技有限公司 | Regenerative medical material for promoting tissue in-situ regeneration and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
US8288344B2 (en) | 2012-10-16 |
CN101264340A (en) | 2008-09-17 |
CA2582551C (en) | 2012-06-05 |
CN101264340B (en) | 2013-09-25 |
US20080226688A1 (en) | 2008-09-18 |
CA2582551A1 (en) | 2008-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8288344B2 (en) | Ceramic composition for filling bone defects | |
CA2457372C (en) | Composition for filling bone defects | |
EP1127581B1 (en) | Malleable paste for filling bone defects | |
US9138509B2 (en) | Composition for filling bone defects | |
US6437018B1 (en) | Malleable paste with high molecular weight buffered carrier for filling bone defects | |
USRE39587E1 (en) | Malleable paste for filling bone defects | |
USRE38522E1 (en) | Malleable paste for filling bone defects | |
US6911212B2 (en) | Malleable putty and flowable paste with allograft bone having residual calcium for filling bone defects | |
US20200368395A1 (en) | Bioactive bone graft substitutes | |
US7045141B2 (en) | Allograft bone composition having a gelatin binder | |
AU782504B2 (en) | Malleable paste with allograft bone reinforcement for filling bone defects | |
US20060198863A1 (en) | Ceramic composition for filling bone defects | |
US6623748B2 (en) | Reverse phase connective tissue repair composition | |
US20060204544A1 (en) | Allograft bone composition having a gelatin binder | |
US20210386910A1 (en) | Demineralized bone matrix having improved handling characteristics | |
US20120205274A1 (en) | Allograft bone composition having a gelatin binder | |
AU784006B2 (en) | Malleable paste for filling bone defects | |
AU2008200841A1 (en) | Composition For Filling Bone Defects |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |